Datasets:

NIHRDataInsights
/

HRCSData

Tasks:

Text Classification

Tags:

medical

biology

License:

Dataset card Data Studio Files Files and versions

xet

Community

Dataset Preview

Duplicate

Split (2)

train

The full dataset viewer is not available (click to read why). Only showing a preview of the rows.

The dataset generation failed because of a cast error

Error code:   DatasetGenerationCastError
Exception:    DatasetGenerationCastError
Message:      An error occurred while generating the dataset

All the data files must have the same columns, but at some point there are 1 new columns ({'HRCS2022_ID'}) and 1 missing columns ({'ID'}).

This happened while the csv dataset builder was generating data using

hf://datasets/NIHRDataInsights/HRCSData/hrcs_test_data.csv (at revision edd523a407fae44691f0b1154fb4b58d928bb1e4), [/tmp/hf-datasets-cache/medium/datasets/89507764079794-config-parquet-and-info-NIHRDataInsights-HRCSData-d0a3e006/hub/datasets--NIHRDataInsights--HRCSData/snapshots/edd523a407fae44691f0b1154fb4b58d928bb1e4/hrcs_test_data.csv (origin=hf://datasets/NIHRDataInsights/HRCSData@edd523a407fae44691f0b1154fb4b58d928bb1e4/hrcs_test_data.csv)]

Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)
Traceback:    Traceback (most recent call last):
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1887, in _prepare_split_single
                  writer.write_table(table)
                File "/usr/local/lib/python3.12/site-packages/datasets/arrow_writer.py", line 675, in write_table
                  pa_table = table_cast(pa_table, self._schema)
                             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2272, in table_cast
                  return cast_table_to_schema(table, schema)
                         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2218, in cast_table_to_schema
                  raise CastError(
              datasets.table.CastError: Couldn't cast
              HRCS2022_ID: string
              FundingOrganisation: string
              FunderAcronym: string
              AwardTitle: string
              AwardAbstract: string
              AwardLayAbstract: string
              RACs: string
              HCs: string
              -- schema metadata --
              pandas: '{"index_columns": [{"kind": "range", "name": null, "start": 0, "' + 1239
              to
              {'FundingOrganisation': Value('string'), 'FunderAcronym': Value('string'), 'AwardTitle': Value('string'), 'AwardAbstract': Value('string'), 'AwardLayAbstract': Value('string'), 'ID': Value('string'), 'RACs': Value('string'), 'HCs': Value('string')}
              because column names don't match
              
              During handling of the above exception, another exception occurred:
              
              Traceback (most recent call last):
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1347, in compute_config_parquet_and_info_response
                  parquet_operations = convert_to_parquet(builder)
                                       ^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 980, in convert_to_parquet
                  builder.download_and_prepare(
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 884, in download_and_prepare
                  self._download_and_prepare(
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 947, in _download_and_prepare
                  self._prepare_split(split_generator, **prepare_split_kwargs)
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1736, in _prepare_split
                  for job_id, done, content in self._prepare_split_single(
                                               ^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1889, in _prepare_split_single
                  raise DatasetGenerationCastError.from_cast_error(
              datasets.exceptions.DatasetGenerationCastError: An error occurred while generating the dataset
              
              All the data files must have the same columns, but at some point there are 1 new columns ({'HRCS2022_ID'}) and 1 missing columns ({'ID'}).
              
              This happened while the csv dataset builder was generating data using
              
              hf://datasets/NIHRDataInsights/HRCSData/hrcs_test_data.csv (at revision edd523a407fae44691f0b1154fb4b58d928bb1e4), [/tmp/hf-datasets-cache/medium/datasets/89507764079794-config-parquet-and-info-NIHRDataInsights-HRCSData-d0a3e006/hub/datasets--NIHRDataInsights--HRCSData/snapshots/edd523a407fae44691f0b1154fb4b58d928bb1e4/hrcs_test_data.csv (origin=hf://datasets/NIHRDataInsights/HRCSData@edd523a407fae44691f0b1154fb4b58d928bb1e4/hrcs_test_data.csv)]
              
              Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)

Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.

FundingOrganisation string	FunderAcronym string	AwardTitle string	AwardAbstract string	AwardLayAbstract null	ID string	RACs string	HCs string
SPARKS	null	Can we treat genetic blood disorders by transplantation of stem cells to the fetus?	Thalassaemia is a genetic blood disease that causes life-threatening anaemia in infants. Blood stem cell transplantation cures the disease but is successful for only 30% of patients. The remainder rely on blood transfusions that cause complications and early death. Transplantation of stem cells in the womb can cure gen...	null	12WTUCL02	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Innovate UK	IUK	Optimisation of human iPS cell-derived platelet manufacture	Platelets are an essential component of blood, involved in homeostasis, clotting and wound healing. Certain medical treatments (esp. chemotherapy) cause a severe reduction in platelet count leading to uncontrolled bleeding. This can be treated with transfusions of platelets isolated from donor blood, but in approximate...	null	38053-276164	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Innovate UK	IUK	Evaluation of an antibody that inhibits thrombosis without causing bleeding	Thrombosis remains a major cause of death and morbidity worldwide. Existing antithrombotics reduce clotting but also increase bleeding, limiting their use. No agents approved for marketing or in clinical trials have been shown to significantly dissociate this bleeding risk from the degree of antithrombosis. This projec...	null	39858-275214	5.1 PHARMACEUTICALS	BLOOD
Innovate UK	IUK	Demonstrating Feasibility of a Novel Diagnostic for Thrombosis Risk	This project will demonstrate the feasibility of applying a sophisticated analysis method for the detection of clinically relevant blood clotting defects in patients to an emerging diagnostic sensor platform technology that can be applied to improve outcomes in many high mortality conditions, particularly common amongs...	null	41192-276328	4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES	BLOOD
Biotechnology and Biological Sciences Research Council	BBSRC	Creating an effective and non toxic blood substitute	Blood transfusion is a life saving technology. However red blood cells: have a limited shelf life; need blood group typing; cannot be used in immune compromised individuals; are not available at the scenes of accidents, battlefields or major emergencies; and are susceptible to viral contamination. Blood transfusion is ...	null	BB/L004232/1	5.4 SURGERY	BLOOD
Chief Scientist Office (Scotland)	CSO	Influence of anaemia on clot structure	Thrombosis is a leading cause of morbidity in a wide range of anaemias, including acquired and congenital haemolytic anaemias[1-10] and anaemic patients with essential thrombocythaemia (ET)[11] and myelofibrosis[12]. The prothrombotic profile in these conditions is multifactorial, however a direct pathogenic role throu...	null	CAF/14/04	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Department of Health (England)	NIHR	Development of outcome tools and an evaluation pathway to monitor clinical progression in young boys with haemophilia	Haemophilia is an inherited disorder characterised by recurrent bleeding into joints, leading to irreversible joint disease and painful deformity. Prophylactic treatment with missing coagulation factors at an estimated cost per child of £100,000 per annum, has significantly reduced, but not alleviated all joint bleedin...	null	CAT/CL10/008	8.1 ORGANISATION AND DELIVERY OF SERVICES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES	BLOOD
Engineering and Physical Sciences Research Council	EPSRC	EPSRC Healthcare Impact Partnership for new blood clotting diagnostics and management	We propose to establish a Healthcare Impact Partnership for research which is stimulated by an unmet clinical need for improved monitoring and prediction of abnormal clotting responses to therapy or disease. Thromboembolic disease and associated blood clotting abnormalities cause significant morbidity and mortality in ...	null	EP/L024799/1	4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES	BLOOD
Engineering and Physical Sciences Research Council	EPSRC	Expanding the limits of biomolecular simulations: revealing the mechanisms of blood clot formation using Fluctuating Finite Element Analysis.	Computational simulation of biomolecules has proven to be a very useful approach during the past few decades, and is now considered essential in broad range of disciplines ranging from the molecular understanding of life to drug discovery. Molecular dynamics is so frequently used to calculate the dynamic behaviour of p...	null	EP/M004228/1	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;1.4 METHODOLOGIES AND MEASUREMENTS	BLOOD
Medical Research Council	MRC	Preclinical evaluation of rAAV encoding a novel highly expressed Factor VIII molecule for haemophilia A gene therapy	The goal of this proposal is to generate sufficient data to support a Phase I/II gene therapy trial for haemophilia A (HA), the most common inherited bleeding disorder that results from mutations in the human factor VIII (hFVIII) gene. We have already developed a new gene therapy approach for a related bleeding disorde...	null	G0902219/1	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Department of Health (England)	NIHR	The HAEM (Haemorrhage and Antifibrinolytics in Emergency Medicine) Project.	Sudden severe bleeding is an important medical problem in the UK and world-wide. Bleeding into the brain after head injury can kill or disable. Some diseases of the digestive system can cause life threatening bleeding and every year tens of thousands of women in developing countries die from severe bleeding after child...	null	HICF-0510-007	6.1 PHARMACEUTICALS	BLOOD
Chief Scientist Office, Scotland	CSO	Oral iron, intravenous iron or discontinuation of therapy for older adults with treatment-unresponsive iron deficiency anaemia - a pilot randomised control trial	Anaemia due to low iron levels is common in older people and can cause tiredness and breathlessness. It is commonly treated with iron tablets. However, iron tablets do not improve anaemia in many people and they have side effects. We do not know what strategy of care is best for patients who do not respond to iron tabl...	null	HRCS2018_04490	6.1 PHARMACEUTICALS	BLOOD
Economic and Social Research Council	ESRC	Inherited blood disorders, globalisation and the promise of genomics: An Indian case-study	Sickle cell and thalassaemia, forms of inherited blood disorders (IBD), classified by the WHO under 'prevention and management of inherited birth defects', have recently been defined as an emergent global health crisis. The pattern of recessive inheritance implies that babies who inherit two copies of a mutant gene (fr...	null	HRCS2018_05272	4.3 INFLUENCES AND IMPACT	BLOOD
Medical Research Council	MRC	Nuclear organisation and erythropoiesis	The organisation of chromatin within the nucleus has a key role to play in the processes of transcription and replication but the mechanisms governing how chromatin domains are established and altered during the course of development and differentiation remain poorly understood. There is a broad consensus that chromati...	null	HRCS2018_10287	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	Gene regulation by distal regulatory elements in Erythropoiesis and the effect of natural sequence variants.	It has become clear over the last 10 years that control of gene expression is very often not determined by the promoter of the gene, but rather by variable numbers of regulatory elements, which are unpredictably distributed in and around the genes themselves. These so called distal regulatory elements are situate away ...	null	HRCS2018_10291	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	Modernising the diagnosis of mucocutaneous bleeding disorders: next generation sequencing of novel loci associated with platelet dysfunction.	Some mucocutaneous bleeding disorders such as von Willebrand disease and the major platelet disorders such as Glanzmann's thrombasthenia are well defined. However the majority of cases are due to undefined causes. Current investigation algorithms lack sufficient sensitivity and specificity to achieve specific diagnoses...	null	HRCS2018_10438	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Transfusion and Treatment of severe Anaemia in African Children: a randomised controlled trial (TRACT)	TRACT is a multicentre randomised controlled trial to identify optimal transfusion strategies and supportive treatment for 3700 African children, aged 2 months to 12 years, presenting to hospital with severe anaemia (defined as haemoglobin (Hb) <6 g/dl). Children will be enrolled at admission to hospital over 2 years i...	null	HRCS2018_10439	6.4 SURGERY	BLOOD
Medical Research Council	MRC	Engineering a new generation of blood substitutes	There is a clinical need, and a financial market, for a long-lasting sterile red blood cell substitute to be used in environments or patient groups where homologous blood is not available or appropriate. Synthetic hemoglobin (Hb) is the best candidate for the oxygen-carrying component of a blood replacement. However, c...	null	HRCS2018_10663	5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	MICA: An open label dose-escalation study of a novel adeno-associated viral vector for gene transfer in subjects with haemophilia A	The goal of this proposal is to conduct a Phase I/II gene therapy trial for haemophilia A (HA), the most common inherited bleeding disorder, which results from mutations in the human factor VIII (hFVIII) gene. The same serotype 8 pseudotyped adeno-associated virus vector (AAV8) that mediated stable (>3 years) therapeut...	null	HRCS2018_10666	6.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	Recombinant proteins for GMP-compatible niche creation to optimize in vitro platelet production for human transfusion	WP1: Identification of candidate membrane-expressed proteins (MExPs) The secreted and membrane-tethered proteins for cell lines that support proplatelet (ProPt) formation by MKs in cocultures that promote have been identified from expression arrays and proteomics analysis. The ectodomain of 400 candidate proteins will ...	null	HRCS2018_10756	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	ADAMTS13 structure and the molecular basis of VWF recognition and cleavage	Von Willebrand factor (VWF) is a large multimeric plasma glycoprotein that is critical for platelet recruitment to sites of blood vessel damage. VWF platelet-tethering function is highly dependent upon its multimeric size, with larger VWF multimers being more haemostatically competent. VWF plasma multimeric size, and c...	null	HRCS2018_10862	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	The role of von Willebrand Factor in endothelial platelet capture	This study will use an in vitro system to study the role of VWF in platelet capture by endothelial cells(EC) and thus its role in atherogenesis. Epidemiological studies of patients with CVD or genetic defects of VWF addressing this have given conflicting results. Animal studies have been suggestive but again incomplete...	null	HRCS2018_10994	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Experimental manipulation of indices of lesion severity in multi-vessel coronary artery disease: Quantitative exploration of collateral influences.	Aims: To test the hypothesis that collateral mediated changes in coronary flow pattern can alter the physiological severity of stenoses in multi-vessel coronary artery disease. Objectives: -To understand how 'two-for-one' stenting occurs (how the severity of a stenosis can be improved without a need for further stentin...	null	HRCS2018_10995	4.2 EVALUATION OF MARKERS AND TECHNOLOGIES	BLOOD
Medical Research Council	MRC	Mechanisms and functions of CRACR2A-L Rab GTPase in vascular endothelial cells	Objective 1: To determine the contribution of CRACR2A-L to Weibel Palade body trafficking. The general strategy for this project will be to use high resolution imaging to quantify and measure the distribution of CRACR2A-L and vWF in endothelial cells. Contribution of CRACR2A-L to Weibel Palade body trafficking in respo...	null	HRCS2018_11118	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Hypoxic pre-conditioning of seeded tissue engineered scaffold to improve in vivo neovascularisation	Aim: To determine if hypoxic pre-conditioning of seeded decellularised trachea scaffold will promote the release of pro-angiogenic cytokines and accelerate angiogenesis. Objectives: 1. Optimising hypoxic pre-conditions - Determine if hypoxic preconditioning of seeded cells promotes pro-angiogenic factors which accelera...	null	HRCS2018_11150	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	The genetic basis and biology of dyskeratosis congenita and bone marrow failure	Dyskeratosis congenita and bone marrow failure are a heterogeneous group of life threatening disorders affecting children and adults. They are unified by the inability of the bone marrow to make an adequate number of mature blood cells and patients die prematurely from infection or bleeding. We hold a large unique inte...	null	HRCS2018_11836	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Development of a novel therapy for Beta-Thalassaemia using CRISPR/Cas9 to edit the major alpha-globin enhancer	Beta-thalassaemia is an inherited anaemia caused by reduced or absent production of the haemoglobin component beta-globin. Despite being one of the first molecular diseases to have its pathophysiology characterised, the management of beta-thalassaemia is far from optimal, limited to supportive therapy for the majority....	null	HRCS2018_11863	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	Understanding granule disorders of myeloid cells by unravelling the interactome and function of the Nbeal2 protein	The regulation of myeloid cell secretory granules has a key role in atherogenesis and thrombosis. Understanding granule function could lead to new treatments for haemostatic and cardiovascular diseases. I will focus on NBEAL2 variants, which cause Gray Platelet Syndrome (GPS), a rare bleeding disorder. Molecular studie...	null	HRCS2018_11871	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	IMPC: Analysis of the role of Cx57 in the regulation of platelet function, haemostasis and thrombosis	Platelets are small cells that control blood clotting. When they encounter cuts or damage to blood vessels they rapidly become sticky and stick to each other. This forms a plug, the first stage of clot formation that stops the bleeding as quickly as possible. Blood vessels become abnormal in cardiovascular disease and ...	null	HRCS2018_11932	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES	BLOOD
Medical Research Council	MRC	IMPC: Phenotyping Cardiovascular Development of Rbms1-null mice	The therapeutic stimulation of new blood vessel growth is considered a promising treatment for diseases in which organs become oxygen starved, for example after a heart attack or stroke and in diabetic vascular eye disease. Moreover, blood vessel function is thought to contribute to neurodegenerative diseases such as A...	null	HRCS2018_11991	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	Role of regulatory elements in the genetic determination of VWF level in Von Willebrand disease and healthy individuals	In the UK there are ~10,000 VWD patients and they mainly present with mucocutaneous bleeding. The ThromboGenomics (TG) high throughput sequencing (HTS) test, introduced as a diagnostic test in the NHS in 2015 identifies causal variants in VWF exons. There is an assumption, partially supported by TG test results that a ...	null	HRCS2018_12095	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Development of highly sensitive methods for defining off target mutations to enable safe gene editing of haematopoietic cells for transplantation	Sites of off target CRISPR-Cas9 nuclease activity will initially be defined in purified genomic DNA. Digenome-seq shows that RGEN cleavage in vitro is a good predictor of off target sites but it uses whole genome sequencing to identify cut sites, making it prohibitively expensive and insensitive. The novel method invol...	null	HRCS2018_12191	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	Molecular mechanism by which the E325K mutation of human KLF1 causes a severe dyserythropoietic anemia, utilising a novel model system of RBC disease	KLF1 is an erythroid specific transcription factor essential for erythropoiesis. In recent years the number of individuals identified with disease phenotypes mapped to KLF1 mutations has increased rapidly. Of these the most severe, a form of dyserythropoietic anemia, is causally linked with the monoallelic mutation E32...	null	HRCS2018_12211	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	How do mutations in non-muscle myosin 2A cause bleeding disorders and other defects?	Over 80 mutations in MYH9 have been described (Human Genome Mutation Database) that collectively cause an autosomal-dominant disorder known as MYH9 disease. MYH9 encodes non-muscle myosin 2A (NM2A). In humans, the outcomes of this disease range from mild to life-threatening. Symptoms include clotting disorders in which...	null	HRCS2018_12214	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Evaluation of the role of ARAP1 in platelet function and thrombosis	Platelets are small cells in the blood that are essential for hemostasis, but can also contribute to thrombosis and cardiovascular disease when activated inappropriately. We have previously shown that platelet hyperactivity can contribute to resistance to anti-platelet therapy, potentially increasing the risk of stroke...	null	HRCS2018_12286	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	IDENTIFICATION OF A NOVEL ANGIOPOIETIN 2 SIGNALLING CENTRE IN THE EMBRYONIC HAEMATOPOIETIC STEM CELL NICHE	Transplantations of haematopoietic stem cells (HSC) have been used in the clinic for several decades to treat various blood disorders. However, a significant shortage of donors for some patient groups means there is urgent need to find alternative sources of HSCs. A key goal of current haematology is the search for met...	null	HRCS2018_12357	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	Non-invasive assessment and management of coronary heart disease - a translational, data driven approach	The aim of the proposed research is to test and improve computational FFR software which can, using non-invasive patient measurements, determine the severity of a coronary artery stenosis. The improvements to the software would include the introduction of more automated, or semi-automated processes. By the end of the p...	null	HRCS2018_12590	4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES	BLOOD
Medical Research Council	MRC	A protein-transcriptome atlas of haematopoiesis across the human life span	The recent development of Cite-Seq technology coupled with the commercialization of dedicated antibody and droplet-based sequencing reagents represent a golden opportunity to generate a comprehensive Cite-Seq dataset to complement ongoing projects across the Human Cell Atlas Initiative. We have assembled a team of PIs ...	null	HRCS2018_12652	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Department of Health and Social Care	NIHR	Transitions from paediatric to adult services for sickle cell disease (SCD): a prospective qualitative study examining young adult patients’ experiences	Transitions from paediatric to adult services cause problems worldwide, particularly among patients with chronic disease and complex health needs requiring integrated care. Transitional care is a key area within the NHS and sickle Cell Disease (SCD) provides an excellent case study for examining transitions. SCD is com...	null	HRCS2018_13706	7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES	BLOOD
Department of Health and Social Care	NIHR	Multicentre, open label, prospective, single arm study of the safety and impact of Eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome	Research Question: In patients on Eculizuamb treatment for aHUS (P) does withdrawal of treatment with monitoring (I) lead to equivalent rates adverse event compared to patients who remain on treatment (C)? If so this would change the way Eculizumab is used for the treatment of aHUS (O). Design: Single arm, open label s...	null	HRCS2018_13863	6.1 PHARMACEUTICALS	BLOOD
Department of Health and Social Care	NIHR	Patiromer for treating hyperkalaemia [ID877]	To appraise the clinical and cost effectiveness of patiromer within its marketing authorisation for treating hyperkalaemia.	null	HRCS2018_14193	6.1 PHARMACEUTICALS	BLOOD
Health Education England	NIHR	Haemarthrosis of the ankle in haemophilia A and B: prevalence, impact and intervention	Haemophilia impairs bleeding control because of an absence of clotting factor VIII (haemophilia A) or factor IX (haemophilia B)1 resulting in bleeding into muscles and joints2. Although treatment with artificial clotting factor has some effect on frequency of bleeds, most patients still experience ongoing spontaneous a...	null	HRCS2018_14639	6.3 MEDICAL DEVICES;2.4 SURVEILLANCE AND DISTRIBUTION	BLOOD
Department of Health and Social Care	NIHR	To produce a cost effective immunoadsorption plasma filter for the production of blood group universal fresh frozen plasma and cryoprecipitate for transfusion.	Currently, plasma transfusion requires the donor and recipient to be blood group compatible. Plasma from donors of blood group AB is regarded as suitable for transfusion to any patient, because it does not contain anti-A or anti-B: if present these antibodies can bind to a patient's red blood cells causing haemolysis a...	null	HRCS2018_14807	5.4 SURGERY	BLOOD
Department of Health and Social Care	NIHR	Lusutrombopag and avatrombopag for Thrombocytopenia (severe, chronic liver disease, surgery) [ID1520]	To systematically review the effectiveness and estimate the cost effectiveness of avatrombopag versus lusutrombopag versus established clinical management without avatrombopag and lusutrombopag (including, but not limited to platelet transfusion) for people with thrombocytopenia associated with chronic liver disease ne...	null	HRCS2018_15839	6.1 PHARMACEUTICALS	BLOOD
Department of Health and Social Care	NIHR	Development Of a haemophiLia PHysiotherapy INtervention for optimum musculoskeletal health (DOLPHIN) - feasibility of a randomised controlled trial	Background: Haemophilia is a rare inherited disorder affecting 1:10,000 of the population, in which the blood does not clot normally, leading to repeated bleeding into joints (haemarthroses) and muscles (haematomas).1 Recurrent haemarthroses trigger a degenerative irreversible process of synovial hypertrophy, articular...	null	HRCS2018_15932	6.7 PHYSICAL	BLOOD
Department of Health and Social Care	NIHR	Halting olfactory haemorrhage with Tranexamic acid in the Emergency Room	Background: Far from being trivial, epistaxis (nosebleed) can be fatal with over 60,000 UK Emergency Department (ED) attendances per year, resulting in over 20,000 emergency hospital admissions (>40,000 hospital bed days) each year. In one third of cases presenting to the ED, bleeding fails to settle with the simple me...	null	HRCS2018_15938	6.1 PHARMACEUTICALS	BLOOD
Department of Health and Social Care	NIHR	A multicentre randomised trial of first line treatment pathways for newly diagnosed immune thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate.	Immune thrombocytopenia (ITP) has an incidence of 2.9/100,000 person-years1. It is an autoimmune condition that presents with bleeding and bruising due to a low platelet count. There is increased consumption and reduced production of platelets due to both antibody and cell mediated autoimmune attack of platelets and me...	null	HRCS2018_16015	6.1 PHARMACEUTICALS	BLOOD
Wellcome Trust	WT	A Device for the removal of circulating autophagic vesicles in patients with sickle cell disease	Sickle Cell Disease(SCD) is the commonest inherited genetic disorder in the UK with 14,000 patients and over 300 affected children born annually. There are three disease modifying treatments available, hydroxyurea, blood transfusion and stem cell transplant. Of these, transfusion is the mainstay of preventative treatme...	null	HRCS2018_20229	5.3 MEDICAL DEVICES	BLOOD
Medical Research Council	MRC	Two tier protection and metabolic genotoxicity during blood production	We investigate how cells and organisms repair highly toxic DNA interstrand crosslinks. In the human inherited illness Fanconi’s anaemia the repair of DNA crosslinks fails, causing developmental defects, bone marrow failure, and marked cancer predisposition. Over the last 5 years our research has made important contribu...	null	HRCS22_01250	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Haematopoietic stem cell fitness mechanisms	Multipotent self-renewing haematopoietic stem cells (HSCs) are essential for human health and the curative potential of HSC transplantation therapies. I joined the MRC Molecular Haematology Unit (MHU) in April 2021 to investigate mechanisms regulating HSC activity and to apply this knowledge to improve therapies for ha...	null	HRCS22_01251	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	MICA: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME)	H-PRIME will be a phase III 2x2x2 factorial randomised partially placebo-controlled trial. We aim to conduct a policy changing trial to address three key interventions that could make a substantial difference to the lives of children born with sickle cell anaemia (SCA) in low-income regions in sub-Saharan Africa. H-PRI...	null	HRCS22_01845	6.1 PHARMACEUTICALS	BLOOD
Medical Research Council	MRC	Developing human model cellular systems for studying Red Blood Cell diseases and as screening platforms	Thalassemia syndromes and sickle cell disease (SCD) represent a significant global health problem and financial burden to health services. Studying these diseases is severely impeded by paucity of suitable and adequate quantities of material from patients, and lack of suitable cell lines. Mouse models of the diseases a...	null	HRCS22_01999	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	Control of blood cell emergence by YAP and environmental cues	The haematopoietic system is maintained throughout adult life by haematopoietic stem cells that produce a constant supply of all blood cells. In the clinic, these stem cells are the cells which upon transplantation successfully restore the blood system in a range of disease. One major limitation to the use of blood ste...	null	HRCS22_02141	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	Switching mammalian genes on and off during development, lineage specification, and differentiation, and its impact on human genetic disease	This programme addresses a key question in biomedical research: how are genes switched on and off during development, lineage commitment, differentiation and maturation? To date we know that this involves the three fundamental regulatory elements of the genome: enhancers, promoters and boundary elements. Here we invest...	null	HRCS22_02270	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	Counteracting hematopoietic ageing by pharmacological inhibition of TGFbeta and IL-6 signaling	Ageing of the hematopoietic system is associated with declining erythropoiesis and lymphopoiesis, leading to decreased adaptive immunity and frequent anemia, together contributing to multiple age-related morbidities, including cognitive decline, decreased muscle strength, cardiovascular problems and susceptibility to i...	null	HRCS22_02274	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	The role of the endothelium in traumatic coagulopathy.	As a clinician specialising in bleeding disorders, and as the Chair of the Major Haemorrhage Committee, I have seen how important it is to develop effective treatments for trauma-related-haemorrhage. Mortality associated with major bleeding is high and the lack of understanding of how coagulopathy develops in patients ...	null	HRCS22_02355	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	Improving cardiovascular outcomes in polycythaemia by risk stratification and targeted therapy.	Thrombosis remains the major cause of morbidity and early mortality in JAK2 positive polycythaemia (PV). Preventative strategies are based on two RCTs which showed benefit of low-dose aspirin and venesection to maintain haematocrit <0.45. Patients considered at higher thrombosis risk are given additional cytoreductive ...	null	HRCS22_02358	4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES	BLOOD
Medical Research Council	MRC	Optimisation of the manufacture of a homogeneous synthetic haemoglobin as a novel Oxygen Therapeutic / Blood Substitute	There is significant clinical need for a synthetic oxygen therapeutic / blood substitute that is both long-lasting and sterile. As haemoglobin (Hb) is the body's natural oxygen carrier the use of cell-free Hb is an ideal starting material for such an agent. However, such Haemoglobin-Based Oxygen Carriers (HBOCs) displa...	null	HRCS22_02379	5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS	BLOOD
Medical Research Council	MRC	Generating platelets in vitro for the clinic: optimisation and added clinical efficacy	The project is divided in 4 workpackages WP1. Identification of efficient hPSC lines. Ghevaert and Eto have tested between them 55 iPSC lines to identify good/bad MK producers. We will carry out whole genome expression and epigegetic study to pinpoint markers that identify good cell lines to facilitate the choice of cl...	null	HRCS22_02599	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	Human blood stem cell expansion: Empowering new technology for stem cell medicine	Despite significant efforts and investment, researchers have largely failed to maintain fully functional HSCs for substantial periods of time. The current state-of-the-art in therapeutic applications is to therefore minimise the amount of time that HSCs are kept outside the body, imposing a number of limitations on cli...	null	HRCS22_02602	5.2 CELLULAR AND GENE THERAPIES	BLOOD
Medical Research Council	MRC	UNDERSTANDING MOLECULAR MECHANISMS UNDERLYING DEVELOPMENT OF HIGHLY REGENERATIVE HUMAN HAEMATOPOIETIC STEM CELLS	Over 50,000 HSC transplantations in clinics are performed annually worldwide, but demand outstrips supply. Despite widespread efforts, the search for methods enabling the generation of bona fide HSCs in vitro has met with limited success, primarily due to poor understanding of molecular mechanisms underlying HSC develo...	null	HRCS22_02734	1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING	BLOOD
Medical Research Council	MRC	A molecular and structural approach to understanding interstrand crosslink incision by the Fanconi anaemia DNA repair pathway	Loss of genomic stability elicits disease and is a trigger for human ageing. During every cell division, structural aberrations in the DNA can block the progression of DNA replication. The inherited syndrome Fanconi anaemia (FA) produces devastating and often lethal clinical features including bone marrow failure, deve...	null	HRCS22_03119	2.1 BIOLOGICAL AND ENDOGENOUS FACTORS	BLOOD
Medical Research Council	MRC	MICA: Development of Boron Doped Diamond Based Transcutaneous Blood Gas Sensors for Improved Patient Ventilation Status Monitoring and Control	Dissolved oxygen and carbon dioxide blood gas levels are key indicators of respiratory health and represent an important diagnostic test for illness severity. Current procedures nearly all involve a direct skin puncture, removal of the blood and analysis in a blood gas analyser. Low numbers of analysers in hospitals me...	null	HRCS22_03129	5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES	BLOOD
Department of Health and Social Care	NIHR	NIHR Research Group on Patient-centred sickle cell disease management in sub-Saharan Africa (PACTS)	Sickle cell disease (SCD) is a genetic disorder affecting 2% of newborns in sub-Saharan Africa (SSA) where >70% of the global disease burden occurs. It is characterised by chronic anaemia, episodes of severe pain, progressive damage to organs (heart, lungs, brain, kidneys) and impaired growth and intellectual developme...	null	HRCS22_05149	7.1 INDIVIDUAL CARE NEEDS;7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT);8.1 ORGANISATION AND DELIVERY OF SERVICES	BLOOD
Department of Health and Social Care	NIHR	The clinical benefits and cost-effectiveness and safety of haematopoietic interventions for patients with anaemia following major emergency surgery: a phase IV, multicentre, multi-arm randomised controlled trial: Peri-op Iron and EPO Intervention Study - POP-I	BACKGROUND TO THE RESEARCH_x000D_ Each year over 100,000 people over 60 years of age in the UK are admitted to hospital for lifesaving emergency operations. Two of the most common emergency operations are for hip fracture and severe abdominal problems. Many of these people have anaemia (a reduced number of red blood ce...	null	HRCS22_05372	6.1 PHARMACEUTICALS	BLOOD
Department of Health and Social Care	NIHR	Randomised trial of Haploidentical Transplantation compared to standard of care for Adults with Sickle Cell Disease	Sickle cell disease (SCD) is one of the most common serious inherited conditions worldwide. It is a disorder in which red blood cells become sickle shaped in conditions of stress. The sickle shape is unable to pass through blood vessels easily, resulting in a blockage. Patients with severe SCD may have many complicatio...	null	HRCS22_05500	6.2 CELLULAR AND GENE THERAPIES	BLOOD
Department of Health and Social Care	NIHR	Artificial intelligence systems to improve the safety, efficiency and clinical outcomes of blood transfusion by the precise genetic matching of patients to blood units	Each year, 1.4 million units of blood are donated, providing transfusion treatment to over 700,000 NHS patients. Transfusion can be life-saving for patients with cancer or inherited red blood cell disorders or after blood loss caused by trauma or childbirth. The formation of antibodies against red blood cell antigens (...	null	HRCS22_05946	7.3 MANAGEMENT AND DECISION MAKING	BLOOD

End of preview.

Data Selection & Splitting

Source: HRCS 2014, 2018, and 2022 direct award datasets.
Quality Filtering:
- Only human-coded abstracts were included.
- Records with abstracts shorter than 75 characters were removed during preprocessing to ensure the model had sufficient text to learn from.
Train/Test Split: The Test Set was isolated using only 2022 data to provide a modern performance benchmark.

Training Data Deduplication

To prevent the model from over-fitting on near-identical entries, a robust deduplication pipeline was implemented:

Vectorization: Character-level TF-IDF vectors were generated from training titles using word-boundary character n-grams (length 3–5).
Similarity Analysis: Near-duplicate titles were identified using a Cosine Similarity threshold of more than or equal to 0.85.
Clustering: Records exceeding this threshold were grouped using a connected-components graph algorithm.
Selection: Only the first occurrence in file order from each group was retained in the training pool.

Leakage Prevention (Train vs. Test)

To ensure the test set provides a truly unseen and honest evaluation, the following steps were taken:

Shared Feature Space: The TF-IDF vectorizer was fit on the combined set of training and test titles.
Cross-Set Comparison: Any training record with a Cosine Similarity threshold of more than or equal to 0.85 to any record in the test set was permanently removed from the training pool.
Test Set Integrity: The test set itself was deduplicated using exact title matching only (no fuzzy matching applied).

Limitation: Short, highly generic grant titles (e.g., "Studentship") may have been deduplicated in the training set due to the similarity threshold.

Downloads last month: 7

Total file size:

68.6 MB

Models trained or fine-tuned on NIHRDataInsights/HRCSData

NIHRDataInsights/HRCSHealthCategories

Text Classification • 0.3B • Updated Mar 10 • 168

NIHRDataInsights/HRCSResearchActivityCodes

Text Classification • 0.3B • Updated Mar 10 • 147 • 1